Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide with Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis After Hematopoietic Stem Cell Transplantation from an Unrelated or Haploidentic Donor
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 21
Healthy Volunteers: f
View:
⁃ 1\. Patients under the age of 21 years with following diseases:
• acute lymphoblastic,
• myeloblastic,
• biphenotypic,
• bilinear leukemia,
• malignant lymphoma,
• myelodysplastic syndrome,
Locations
Other Locations
Russian Federation
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov
RECRUITING
Moscow
Contact Information
Primary
Maschan Michael,, MD, PhD
mmaschan@yandex.ru
+79166512145
Time Frame
Start Date: 2024-07-10
Estimated Completion Date: 2026-10-10
Participants
Target number of participants: 50
Treatments
Experimental: Prevention of GVHD: Cyclophosphamide, Abatacept, Vedolizumab, Ruxolitinib
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen
Related Therapeutic Areas
Sponsors
Leads: Federal Research Institute of Pediatric Hematology, Oncology and Immunology